Volume 3, Issue 3 1800287
Review

Improving Cancer Vaccine Efficiency by Nanomedicine

Junyu Cai

Junyu Cai

State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, 201203 Shanghai, China

China State Institute of Pharmaceutical Industry, 285 Gebaini Road, 201203 Shanghai, China

Search for more papers by this author
Hao Wang

Hao Wang

China State Institute of Pharmaceutical Industry, 285 Gebaini Road, 201203 Shanghai, China

Search for more papers by this author
Dangge Wang

Corresponding Author

Dangge Wang

State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, 201203 Shanghai, China

E-mail: [email protected], [email protected]Search for more papers by this author
Yaping Li

Corresponding Author

Yaping Li

State Key Laboratory of Drug Research and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Road, 201203 Shanghai, China

E-mail: [email protected], [email protected]Search for more papers by this author
First published: 08 January 2019
Citations: 25

Abstract

Cancer vaccines, which have been widely investigated in the past few decades, are one of the most attractive strategies for cancer immunotherapy. Through the precise delivery of antigens and adjuvants to lymphoid organs or lymphocytes via nanotechnology, innate and adaptive immunity can be boosted to prevent the growth and relapse of malignant tumors. Indeed, nanomedicine offers great opportunities to improve the efficiency of vaccines. Various functional platforms are used to deliver small molecules, peptides, nucleic acids, and even whole cell antigens to the target area of interest, achieving enhanced antitumor immunity and durable therapeutic benefits. Herein, the recent progress in cancer vaccines based on nanotechnology is summarized. Novel platforms used for delivering tumor antigens, promoting adjuvant functions, and combining other therapeutic strategies are discussed. Moreover, possible striving directions and major challenges of nanomedicine for vaccination are also reviewed.

Conflict of Interest

The authors declare no conflict of interest.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.